CGL
VIR icon

Clarius Group LLC’s Vir Biotechnology VIR Stock Holding History

Clarius Group LLC’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.67M Sell
608,200
-11,112
-2% -$66.2K 0.21% 50
2025
Q3 		$3.54M Buy
619,312
+1,777
+0.3% +$9.09K 0.21% 50
2025
Q2 		$3.11M Buy
617,535
+560,342
+980% +$3M 0.18% 59
2025
Q1 		$371K Hold
57,193
– – 0.02% 299
2024
Q4 		$420K Hold
57,193
– – 0.03% 250
2024
Q3 		$428K Hold
57,193
– – 0.03% 240
2024
Q2 		$509K Hold
57,193
– – 0.04% 212
2024
Q1 		$579K Buy
57,193
+7,182
+14% +$73.1K 0.04% 197
2023
Q4 		$503K Sell
50,011
-7,182
-13% -$65.6K 0.04% 235
2023
Q3 		$536K Hold
57,193
– – 0.05% 207
2023
Q2 		$1.4M Hold
57,193
– – 0.11% 99
2023
Q1 		$1.33M Hold
57,193
– – 0.11% 103
2022
Q4 		$1.45M Hold
57,193
– – 0.13% 95
2022
Q3 		$1.1M Buy
57,193
+18,514
+48% +$471K 0.11% 112
2022
Q2 		$985K Sell
38,679
-3,805
-9% -$88.8K 0.1% 126
2022
Q1 		$1.78M Hold
42,484
– – 0.14% 89
2021
Q4 		$1.78M Sell
42,484
-183
-0.4% -$7.17K 0.14% 89
2021
Q3 		$1.86M Buy
42,667
+5,722
+15% +$248K 0.17% 72
2021
Q2 		$1.75M Buy
36,945
+1,588
+4% +$72.2K 0.16% 79
2021
Q1 		$1.81M Buy
+35,357
New +$1.91M 0.18% 65

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Clarius Group LLC's VIR Position: Q4 2025 in Review

Clarius Group LLC reduced its Vir Biotechnology (VIR) stake by 1.8% in Q4 2025, selling an estimated $66.2K and leaving 608,200 shares worth $3.67M. The position accounts for 0.21% of the portfolio, ranked #50.

Clarius Group LLC first reported a position in VIR in Q1 2021 and has held it in 20 quarters since. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

  • Clarius Group LLC held 608,200 shares of Vir Biotechnology worth $3.67M as of Q4 2025.
  • Clarius Group LLC sold 11,112 Vir Biotechnology shares in Q4 2025, an estimated $66.2K.
  • Vir Biotechnology made up 0.21% of Clarius Group LLC's portfolio in Q4 2025, its #50 holding.
  • Clarius Group LLC first reported a position in Vir Biotechnology in Q1 2021 and has held it in 20 quarters since.
  • 218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.